Hann departs as Biomet details initial findings from stock option probe
This article was originally published in Clinica
Preliminary investigations by Biomet into its stock option grants over the past 11 years have led to the departure of Daniel Hann, the company's former general counsel who served as interim CEO until February 26, when he became executive vice-president of administration.
You may also be interested in...
OIG will focus on successful drugs that have been repurposed as orphans, noting nine of the 10 top selling drugs have both orphan and non-orphan indications.
Switzerland’s SIX exchange-listed drug development company, Basilea, is moving two new oncology candidates along its R&D pipeline, supported by strong revenues from two partnered anti-infective products.
Recommendations from the Alliance for Regenerative Medicine aim to improve cross-border healthcare to ensure patients can access advanced therapies.